Tricuspid regurgitation
Tricuspid regurgitation means blood flows backward from the right ventricle into the right atrium because the tricuspid valve does not close properly. A review divides it into primary and secondary (functional) origins, and says primary tricuspid regurgitation is mostly caused by infective endocarditis, leaflet perforation, entrapment after device placement and congenital abnormalities. The review says the natural cause of the secondary form is not well understood and that underdiagnosis is likely, and that symptoms such as ascites, edema and hepatomegaly usually appear late, which makes assessment challenging.
Also called Tricuspid valve insufficiency
- Condition
- In this atlas
Overview
Technical summary
MeSH D014262 is named Tricuspid Valve Insufficiency (last updated 2007-07-09); its scope note gives the definition used here. The second source is the abstract of a 2021 open-access review of secondary tricuspid regurgitation (CC BY 4.0), used for its first four sentences. The abstract states no frequency or outcome figures, so this record gives none. The abstract read does not cover treatment, so this record gives none. It is not a guideline and carries no recommendation.
Burden
No burden claims are published.
Claims and evidence
No claims are published for this condition yet.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: TriClip
Applies to Adult Adults with symptomatic severe tricuspid regurgitation, randomized in TRILUMINATE Pivotal
Population, setting and follow-up
- Patients 18 years or older (registry minimum age) with symptomatic severe tricuspid regurgitation, 350 of whom were randomized 1:1 at 65 centers across the United States, Canada and Europe (175 to each group). The abstract gives a mean age of 78 years, with 54.9% women. The registry record also covers a single-arm cohort and a continued access study. The detailed inclusion and exclusion criteria are in the registry record and were not extracted.
- 65 centers across the United States, Canada and Europe (abstract)
- United States, Canada and Europe
- Registry minimum age 18 years; mean age 78 years (abstract)
In TRILUMINATE Pivotal, 350 patients with symptomatic severe tricuspid regurgitation were randomized 1:1 at 65 centers to transcatheter edge-to-edge repair (the TriClip device) plus medical therapy or to medical therapy alone (175 patients in each group). The primary end point, a hierarchical composite, consisted of all-cause death or tricuspid-valve surgery, heart failure hospitalization, and an improvement of at least 15 points on the Kansas City Cardiomyopathy Questionnaire (a quality-of-life score) at 1 year. The result favored repair, with a win ratio of 1.48 (95% CI 1.06 to 2.13, P = 0.02). The two groups did not appear to differ in the frequency of death or tricuspid-valve surgery, or in how often patients were hospitalized for heart failure. The quality-of-life score changed by 12.3 points with repair and 0.6 points in the control group. At 30 days, tricuspid regurgitation was of moderate severity or less in 87.0% of the repair group and 4.8% of the control group. 98.3% of the patients who had the procedure had no major adverse events at 30 days.Limitations. Funded by Abbott; the registry lists Abbott Medical Devices as lead sponsor and FDA lists ABBOTT MEDICAL as applicant for the device. The registry records masking of the outcomes assessor only. The abstract reports no apparent difference in death or tricuspid-valve surgery, or in hospitalization for heart failure, so the benefit shown is in the combined score, in quality of life and in the severity of the regurgitation. The abstract does not say how much each component contributed to the win ratio. The FDA indication is for quality of life and function, not for survival or hospitalization. The result is at 1 year. Only the abstract was read.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 30
Record details
- Record id
cardio:tricuspid-regurgitation- Content hash
fc0b91438c86bacec1fdb14e13a7eeeaf8245033b43d27fbc3d6c116a7f7155f